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Summary. Commonly employed tissue processing 
techniques can significantly alter tissue drug distribution 
patterns for liposomal encapsulated drugs by virtue of 
drug leakage via loss of membrane integrity. We report 
here a method that has been developed to determine the 
fluorescence of bioavailable doxorubicin (DOX) in 
tissues after administration of liposomal DOX 
formulations. A non-perturbing confocal fluorescence 
microscopy (CFM) technique with image processing 
analysis was used with unprocessed fresh tissues. This 
method takes advantage of the fact that considerable 
quenching occurs when DOX is within liposomes, 
leading to the selective visualization of the fluorescence 
due to DOX released from liposomes. We demonstrate 
that fresh tissue confocal imaging can be applied to 
provide detailed drug distribution information with 
improved accuracy and is a superior method for 
analyzing tissue distribution of liposome entrapped 
fluorescent agents. 
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Liposomes have been developed as drug carriers for 
a number of therapeutic agents such as anticancer drugs 
(Mayer et al., 1989, 1990, 1997; Rahman et al., 1990; 
Cowens et al., 1993; Adlakha-Hutcheon et al., 1999; 
Lim et al., 2000; Tardi et al., 2000), antimicrobial agents 
(Lopez-Berestein and Juliano, 1987; Vincent et al., 1992; 
Pinto-Alphandary et al., 2000), genes (Felgner and 
Ringold, 1989; Rose et al., 1991; Hyde et al., 1993; 
Singhal and Huang, 1994; Dass et al., 2000; Harvie et 
al., 2000; Kawaura et al., 2000), and antisense 
oligonucleotides (Bennett et al., 1992; Leserman et al., 
1994; Islam et al., 2000). This is because liposomes 
provide the potential for 1) increased stability of the 
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encapsulated agent, 2) a circulating microreservoir or 
depot of the encapsulated drug, releasing it as a function 
of time (sustained release), 3) increased selectivity of 
drug delivery to the tumor site, and 4) reduced peak free 
drug levels and decreased exposure to healthy tissues. 
Liposomes are particularly effective in anticancer 
therapy because of enhanced site specific delivery to 
solid tumors. Vesicles of size less than 200 nm can 
passively extravasate through the gaps in the endothelial 
layer and accumulate in sites of tumor growth. This is 
because blood vessels associated with disease sites such 
as tumors are characterized by frequent interruptions 
along the endothelial cell lining, which is permeable to 
many circulating macromolecules. Macromolecules may 
leak through these "fenestrae" or gaps (Kohn et al., 
1992) or endothelial cell facilitated transcytosis may 
occur (Huang et al., 1993). Liposomes with long 
circulation life times exhibit extended access to the 
openings in the endothelial lining which can often lead 
to increased accumulation in such extravascular sites of 
disease (Gabizon and Papahadjopolous, 1988; Gabizon 
et al., 1990; Gabizon, 1992). Liposome extravasation 
and accumulation in solid tumors has been well 
documented by numerous laboratories using a wide 
variety of tumor types (Gabizon and Papahadjopolous, 
1988; Allen et al., 1989; Mayer et al., 1989; Gabizon, 
1992; Wu et al., 1993; Yuan et al., 1994). 
Tumor drug localization methods used in the past to 
assess intra-tissue distribution properties for liposomal 
drugs have generally utilized techniques wherein the 
excised tumor tissue is subjected to standard tissue 
processing methodologies for conventional 
immunohistochemical or fluorescence microscopy 
(Perez-Soler et al., 1987; Huang et al., 1992; Forssen et 
al., 1996). This procedure may utilize a tissue fixative, a 
cryofixation step and/or severa1 washing steps (Mayer et 
al., 1997). Even with relatively mild processing, these 
conditions may disrupt the liposomal bilayer and cause 
drug leakage, leading to significant alterations in tissue 
distribution patterns for liposomal encapsulated drugs 
compared to distribution in the original tissue specimen. 
For the fluorescent anticancer compound doxorubicin 






